GC
PRQR icon

Guggenheim Capital’s ProQR Therapeutics PRQR Stock Holding History

Guggenheim Capital’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.8K Buy
27,644
+10,420
+60% +$17.1K ﹤0.01% 1593
2025
Q4 		$34.8K Buy
+17,224
New +$40.3K ﹤0.01% 1739

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Guggenheim Capital's PRQR Position: Q1 2026 in Review

Guggenheim Capital increased its ProQR Therapeutics (PRQR) stake by 60% in Q1 2026, buying an estimated $17.1K and bringing the position to 27,644 shares worth $44.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1593.

Guggenheim Capital first reported a position in PRQR in Q4 2025 and has held it in 2 quarters since. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Guggenheim Capital held 27,644 shares of ProQR Therapeutics worth $44.8K as of Q1 2026.
  • Guggenheim Capital bought 10,420 ProQR Therapeutics shares in Q1 2026, an estimated $17.1K.
  • ProQR Therapeutics made up ﹤0.01% of Guggenheim Capital's portfolio in Q1 2026, its #1593 holding.
  • Guggenheim Capital first reported a position in ProQR Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.